VK2735

Areas of active research — not promised effects

Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.

Related by research scope · open each to compare

VK2735 is under active clinical investigation (Phase 3) but has not been approved by the FDA. No NDA has been filed as of mid-2026; approval is projected no earlier than 2028 based on the VANQUISH Phase 3 timeline. It is not available for prescribing, compounding, or commercial distribution outside of authorized clinical trials.

Transparent blend · bci-1.0 · never paid-placement

Primary name

VK2735

Origin

Synthetic peptide developed by Viking Therapeutics; structurally engineered to bind both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Available in two investigational formulations: weekly subcutaneous injection and daily oral tablet.

Appearance

Not publicly characterized; likely white to off-white lyophilized powder (typical of synthetic peptide API) — unconfirmed

Solubility

Aqueous solubility not publicly reported; as a peptide intended for subcutaneous…

Sequence not available in current seed.

Stability: Not publicly reported. Registry identity (PubChem CID, InChIKey, sequence) is not publicly confirmed as of mid-2026; compound is manual_pending in curation.

Vial sizes

null mg

Purity grades

Salt forms

Free base (primary)

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

How much research exists, and of what maturity — never a verdict on whether it works.

Mechanism of action

• VK2735 simultaneously activates GLP-1 receptors and GIP receptors
• GLP-1 receptor engagement reduces appetite via hypothalamic signaling, slows gastric emptying, and promotes glucose-dependent insulin secretion
• GIP receptor co-activation provides complementary incretin effects and may improve tolerability relative to selective GLP-1 agonism
• The combined receptor engagement is mechanistically analogous to tirzepatide, though VK2735 is a structurally distinct molecule with a different peptide backbone and pharmacokinetic profile

Pharmacokinetics (ADME)

Half-life

Approximately 170–250 hours following subcutaneous administration (Phase 1 data; Viking Therapeutics press release, March 2023)

PK–PD note: Tmax approximately 75–90 hours post-subcutaneous dose; supports once-weekly SC dosing. Oral formulation PK not fully published; daily tablet dosing used in Phase 2 VENTURE-Oral (NCT06828055). Approxim…

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Bays HE et al. Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study. Obesity (Silver Spring). 2026;34(3):537-549. PMID 41508550. — Primary trial report (RCT), not a systematic review; the single indexed PubMed entry for VK2735.
• Wikipedia: VK2735 — Aggregator overview; describes dual GLP-1/GIP agonism and tirzepatide-comparable mechanism.
• Superpower Guide: VK2735 — A Dual GLP-1/GIP Receptor Agonist in Clinical Development — Secondary aggregator; states VK2735 is not FDA-approved as of April 2026 and is in active Phase 3 development.

5 registered trials — 0 currently recruiting.

Phase 2
NCT06068946
VK2735 for Weight Management Phase 2

COMPLETED

Phase 2
NCT06828055
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

COMPLETED

Phase 1
NCT05203237
Phase 1 Study to Evaluate the Safety and Tolerability of VK2735

COMPLETED

Phase 3
NCT07104383
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

ACTIVE_NOT_RECRUITING

Phase 3
NCT07104500
VK2735 for Weight Management Phase 3

ACTIVE_NOT_RECRUITING

Summary (literature)

Across Phase 1 (NCT05203237) and Phase 2 VENTURE (NCT06068946), the predominant adverse event class was gastrointestinal (GI): nausea was reported in approximately 43% of SC VK2735-treated participants versus approximately 20% with placebo; vomiting in approximately 18% versus 0%…

WADA status

Not specifically listed as prohibited. GLP-1/GIP dual receptor agonists, including tirzepatide and investigational analogs such as VK2735, are not identified as…

Dominant research route: Subcutaneous (once-weekly injection) is the lead formulation in Phase 3 VANQUISH; oral tablet is a parallel formulation in Phase 2/3 development.

Phase 1 SAD/MAD, Phase 2 VENTURE (NCT06068946), Phase 3 VANQUISH program initiated June 2025 — adults with obesity/overweight; once-weekly injection

Bioavailability: Following single subcutaneous doses, VK2735 demonstrated a half-life of approximately 170 to 250 hours and a Tmax ranging from approximately 75 to 90 hours, with excellent therapeutic exposures (per Viking pipeline page).

VENTURE was a phase 2, randomized, double-blind, placebo-controlled, dose-ranging study of weekly subcutaneous VK2735 in adults with obesity or overweight and ≥1 weight-related comorbidity (NCT06068946); published in Obesity 2026. The VANQUISH Phase 3 program assesses VK2735 administered by subcutaneous injection once weekly for 78 weeks.

Phase 1 MAD (28 days once-daily tablet, healthy adults BMI≥30), Phase 2 VENTURE-Oral Dosing (13 weeks once-daily tablet, adults with obesity) — results reported Aug 2025

Bioavailability: Viking states in vivo data suggest therapeutic plasma levels of VK2735 may be achieved via oral dosing; the oral tablet formulation demonstrated dose-dependent reductions in mean body weight in Phase 1 MAD and Phase 2 VENTURE-Oral. No absolute oral bioavailability fraction is disclosed in retrieved sources.

The oral formulation is a tablet dosed once daily. Phase 2 VENTURE-Oral Dosing was a randomized, double-blind, placebo-controlled multicenter study evaluating safety, tolerability, pharmacokinetics, and weight loss efficacy of VK2735 dosed as an oral tablet once daily for 13 weeks; up to 12.2% mean weight loss observed at 13 weeks. Viking plans to advance oral VK2735 into Phase 3 development.

In vivo studies in diet-induced obese (DIO) mice presented at ObesityWeek 2021

Bioavailability: Data demonstrated improvements in the metabolic profile of DIO mice treated with Viking's compounds compared to control cohorts (route of administration in animal studies not specified as subcutaneous in retrieved sources; listed here as preclinical mechanistic evidence).

VK2735 was selected from a series of internally developed dual GLP-1/GIP receptor agonists evaluated in in vivo studies; results presented at ObesityWeek 2021 highlighted promising effects in DIO mice.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Researched storefront prices, bucketed

What each test proves — general guidance, plus this compound's researched purity data

Independent labs cited for this compound

No recalls, enforcement actions, criminal cases, or counterfeit-specific events identified for VK2735. The compound is an investigational new drug with no FDA approval and no legal compounding pathway (503A/503B) as of mid-2026; none found.

Buyer red-flag checklist

• VK2735 is not FDA-approved and has no legal prescribing or compounding route in the United States; any commercial sale outside clinical trials is unauthorized.
• No 503A/503B compounding pathway exists for VK2735; compounded or 'research-grade' VK2735 offered online is not from the sponsor and lacks verified quality data.
• Unregulated/grey-market GLP-1/GIP peptides sold online are not FDA approved and may carry safety and quality risks (general class warning, not VK2735-specific).
• No independent third-party purity/identity COAs (Janoshik/MZ Biolabs/Finnrick) were found for VK2735; purity claims by non-sponsor vendors cannot be verified.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No independent lab tests (Janoshik, MZ Biolabs, Finnrick) specific to VK2735 were located. VK2735 is a Viking Therapeutics-proprietary investigational compound not legally sold outside clinical trials, so no grey-market purity/underdosing dataset exists for this specific molecule.

• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• investor-heavy skew (many commenters hold VKTX stock)
• trial-participant self-selection (positive responders more likely to post)
• small sample of firsthand users
• aggregator-compiled secondhand sentiment

Manually researched from reddit, x— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

Investigational dual GLP-1/GIP receptor co-agonist (Viking Therapeutics) in Phase 3 trials for obesity; not approved in any jurisdiction as of mid-2026. Approximately 1 articles are indexed (literature last scanned 2026-05-29). US regulatory status: Investigational (IND); not FDA-approved. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet